Molecular markers of adrenocortical tumors

Journal of Surgical Oncology

Volumn 106, Issue 5, 2012, Pages 549-556

  Jain, Meenu ^a   Rechache, Nesrin ^a   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

adrenal neoplasm; adrenocortical carcinoma; CGH; diagnosis; epigenetics; genomics; methylation; miRNA; mRNA

Indexed keywords

APC PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; MICRORNA; MOLECULAR MARKER; PROTEIN P53; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; BECKWITH WIEDEMANN SYNDROME; CARNEY COMPLEX; CHROMOSOME 11P; CHROMOSOME 5Q; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; FAMILIAL CANCER; GARDNER SYNDROME; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; HUMAN; MEDICAL LITERATURE; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; REVIEW;

ADRENAL CORTEX NEOPLASMS; ANIMALS; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866422757     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23119     Document Type: Review

References (66)

1. Kloos RT, Gross MD, Francis IR, et al.: Incidentally discovered adrenal masses. Endocr Rev 1995; 16: 460-484.
2. Kuruba R, Gallagher SF:, Current management of adrenal tumors. Curr Opin Oncol 2008; 20: 34-46. (Pubitemid 350190979)
3. Libe R, Bertherat J:, Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005; 153: 477-487. (Pubitemid 41568145)
4. Gallagher SF, Wahi M, Haines KL, et al.: Trends in adrenalectomy rates, indications, and physician volume: A statewide analysis of 1816 adrenalectomies. Surgery 2007; 142: 1011-1021 discussion 1011-21. (Pubitemid 350184113)
5. Murphy MM, Witkowski ER, Ng SC, et al.: Trends in adrenalectomy: A recent national review. Surg Endosc 2010; 24: 2518-2526.
6. Saunders BD, Wainess RM, Dimick JB, et al.: Trends in utilization of adrenalectomy in the United States: Have indications changed ? World J Surg 2004; 28: 1169-1175. (Pubitemid 40109871)
7. Patterson EE, Holloway AK, Weng J, et al.: MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011; 117: 1630-1639.
8. Soon PS, Tacon LJ, Gill AJ, et al.: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009; 15: 7684-7692.
9. Baehner FL, Lee M, Demeure MJ, et al.: Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy. J Surg Oncol 2011; 103: 563-573.
10. Igaz P, Wiener Z, Szabõ P, et al.: Functional genomics approaches for the study of sporadic adrenal tumor pathogenesis: Clinical implications. J Steroid Biochem Mol Biol 2006; 101: 87-96. (Pubitemid 44322042)
11. Bertherat J, Bertagna X:, Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 2009; 23: 261-271.
12. Soon PS, McDonald KL, Robinson BG, et al.: Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008; 13: 548-561. (Pubitemid 351872872)
13. Herbet M, Feige JJ, Thomas M:, Insights into the role of genetic alterations in adrenocortical tumorigenesis. Mol Cell Endocrinol 2009; 300: 169-174.
14. Herrmann LJ, Heinze B, Fassnacht M, et al.: TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97: E476-E485.
15. Barlaskar FM, Hammer GD:, The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord 2007; 8: 343-348.
16. Bertherat J, Groussin L, Sandrini F, et al.: Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 2003; 63: 5308-5319. (Pubitemid 37139845)
17. Berthon A, Martinez A, Bertherat J, et al.: Wnt/beta-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol 2012; 351: 87-95.
18. Ragazzon B, Libé R, Gaujoux S, et al.: Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 2010; 70: 8276-8281.
19. Tissier F, Cavard C, Groussin L, et al.: Mutations of beta-catenin in adrenocortical tumors: Activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005; 65: 7622-7627. (Pubitemid 41297234)
20. Slater EP, Diehl SM, Langer P, et al.: Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 2006; 154: 587-598.
21. de Reynies A, Assié G, Rickman DS, et al.: Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009; 27: 1108-1115.
22. Fernandez-Ranvier GG, Weng J, Yeh RF, et al.: Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg 2008; 143: 841-846 discussion 846.
23. Fernandez-Ranvier GG, Weng J, Yeh RF, et al.: Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J Surg 2008; 32: 873-881.
24. Soon P, Gill AJ, Benn DE, et al.: Microarray gene expression and immunohistochemistry analyses of adrenocortical tumours identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 2009; 16: 573-583.
25. de Fraipont F, El Atifi M, Cherradi N, et al.: Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005; 90: 1819-1829. (Pubitemid 40464057)
26. Velazquez-Fernandez D, Laurell C, Geli J, et al.: Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005; 138: 1087-1094. (Pubitemid 41797349)
27. West AN, Neale GA, Pounds S, et al.: Gene expression profiling of childhood adrenocortical tumors. Cancer Res 2007; 67: 600-608. (Pubitemid 46192198)
28. Giordano TJ, Thomas DG, Kuick R, et al.: Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003; 162: 521-531. (Pubitemid 36267859)
29. Giordano TJ, Kuick R, Else T, et al.: Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009; 15: 668-676.
30. Almeida MQ, Fragoso MCBV, Lotfi CFP, et al.: Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 2008; 93: 3524-3531.
31. Fassnacht M, Libé R, Kroiss M, et al.: Adrenocortical carcinoma: A clinician's update. Nat Rev Endocrinol 2011; 7: 323-335.
32. Kolomecki K, Stepien H, Bartos M, et al.: Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul 2001; 35: 9-16. (Pubitemid 33711948)
33. Soon PS, Gill AJ, Benn DE, et al.: Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 2009; 16: 573-583.
34. Tacon LJ, Soon PS, Gill AJ, et al.: The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors. J Clin Endocrinol Metab 2009; 94: 4591-4599.
35. Rizk-Rabin M, Assie G, Rene-Corail F, et al.: Differential expression of parathyroid hormone-related protein in adrenocortical tumors: Autocrine/paracrine effects on the growth and signaling pathways in H295R cells. Cancer Epidemiol Biomarkers Prev 2008; 17: 2275-2285.
36. Weismann D, Briese J, Niemann J, et al.: Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol 2009; 218: 232-240.
37. Sbiera S, Schmull S, Assie G, et al.: High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 2010; 95: E161-E171.
38. Ragazzon B, Assie G, Bertherat J:, Transcriptome analysis of adrenocortical cancers: From molecular classification to the identification of new treatments. Endocr Relat Cancer 2011; 18: R15-R27.
39. Szabo PM, Tamási V, Molnár V, et al.: Meta-analysis of adrenocortical tumour genomics data: Novel pathogenic pathways revealed. Oncogene 2010; 29: 3163-3172.
40. Zsippai A, Rita Szabõ D, Szabõ PM, et al.: mRNA and microRNA expression patterns in adrenocortical cancer. Am J Cancer Res 2011; 1: 618-628.
41. Morimoto R, Satoh F, Murakami O, et al.: Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008; 55: 49-55. (Pubitemid 351520179)
42. Waldmann J, Feldmann G, Slater EP, et al.: Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer 2008; 99: 1900-1907.
43. Barzon L, Masi G, Pacenti M, et al.: Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Arch 2008; 452: 181-191.
44. Shen XC, Gu CX, Qiu YQ, et al.: Estrogen receptor expression in adrenocortical carcinoma. J Zhejiang Univ Sci B 2009; 10: 1-6.
45. Fragoso MC, Almeida MQ, Mazzuco TL, et al.: Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: Validation in a Brazilian cohort of adult and pediatric patients. Eur J Endocrinol 2012; 166: 61-67.
46. Volante M, Sperone P, Bollito E, et al.: Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol 2006; 19: 1563-1569. (Pubitemid 44789924)
47. Fenske W, Völker HU, Adam P, et al.: Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 2009; 16: 919-928.
48. Ronchi CL, Sbiera S, Kraus L, et al.: Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 2009; 16: 907-918.
49. Tombol Z, Szabõ PM, Molnár V, et al.: Integrative molecular bioinformatics study of human adrenocortical tumors: MicroRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 2009; 16: 895-906.
50. Doghman M, El Wakil A, Cardinaud B, et al.: Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 2010; 70: 4666-4675.
51. Schmitz KJ, Helwig J, Sheu SY, et al.: Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol 2011; 64: 529-535.
52. Singh P, Soon PS, Feige JJ, et al.: Dysregulation of microRNAs in adrenocortical tumors. Mol Cell Endocrinol 2012; 351: 118-128.
53. Cherradi N, Chabre O, Feige JJ:, Role of miRNA in ACC. Session: Molecular Pathogenesis of ACC-new insights from array studies. In: International Adrenal Cancer Symposium Feb 18-19, Wurzburg, Germany (abstract). 2011.
54. Stephan EA, Chung TH, Grant CS, et al.: Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 2008; 7: 425-431. (Pubitemid 351302536)
55. Barreau O, de Reynies A, Wilmot-Roussel H, et al.: Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: An integrated genomic approach. J Clin Endocrinol Metab 2012; 97: E301-E311.
56. Bielinska M, Parviainen H, Kiiveri S, et al.: Review paper: Origin and molecular pathology of adrenocortical neoplasms. Vet Pathol 2009; 46: 194-210.
57. Egger G, Liang G, Aparicio A, et al.: Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-463. (Pubitemid 38715140)
58. Bock C, Paulsen M, Tierling S, et al.: CpG island methylation in human lymphocytes is highly correlated with DNA sequence, repeats, and predicted DNA structure. PLoS Genet 2006; 2: e26.
59. Esteller M:, Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
60. Jones PA, Baylin SB:, The epigenomics of cancer. Cell 2007; 128: 683-692. (Pubitemid 46273572)
61. Johnstone RW:, Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-299. (Pubitemid 37361445)
62. Volante M, Buttigliero C, Greco E, et al.: Pathological and molecular features of adrenocortical carcinoma: An update. J Clin Pathol 2008; 61: 787-793. (Pubitemid 351969722)
63. Patterson EE, Holloway AK, Weng J, et al.: MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2010; 117: 1630-1639.
64. Ozata DM, Caramuta S, Velázquez-Fernández D, et al.: The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011; 18: 643-655.
65. Bussey KJ, Demeure MJ:, Genomic and expression profiling of adrenocortical carcinoma: Application to diagnosis, prognosis and treatment. Future Oncol 2009; 5: 641-655.
66. Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, Zhang L, Nilubol N, Stratakis CA, Meltzer PS, Kebebew E,. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab 2012. [Epub ahead of print] PMID: 22472567.